Immunology startup Parallel Bio has released a model of the human immune system that is said to capture the way immunotherapies affect the body more accurately than animals. The so-called “Clinical Trial in a Dish” can purportedly save drug companies up to $1 billion and more than six years of development time.

It’s not a double album release, but it’s a close runner-up: The pivotal SWIFT-1 and SWIFT-2 trials have shown that GSK’s long-acting asthma treatment reduces attacks.

A six-month trial showed that Boston Scientific’s pairing of modular, wireless implants for managing discordant cardiac rhythms—and correcting dangerous ones—could be a successful approach, and the devicemaker has its heart set on an FDA approval for the system in 2025.

Three months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis (PBC) med, Gilead Sciences has presented a fresh slice of data as a reminder of seladelpar’s potential while an FDA decision is pending.

Endeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis (IPF) study, sending a sonic pulse through a sector currently dominated by drugs that only slow the decline of the disease.

The new year burst of biotech IPOs may have sputtered out months ago, but Rapport Therapeutics is a reminder that companies are still willing to test the waters of the public markets.

Bayer’s master plan for its OASIS program is coming together, with the German drugmaker posting phase 3 data that suggest it could challenge Astellas for a recently unlocked menopause market.

Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its potential compatibility—going much further than the traditional positive and negative blood types of A, B, AB and O.

On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible competitor.

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a breakthrough designation from the FDA.